WVE Relative Valuation
WVE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, WVE is overvalued; if below, it's undervalued.
Historical Valuation
WAVE Life Sciences Ltd (WVE) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -5.03. The fair price of WAVE Life Sciences Ltd (WVE) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 7.14 USD , WAVE Life Sciences Ltd is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：7.14
Fair
Undervalued
-6.53
PE
1Y
3Y
5Y
Trailing
Forward
-5.23
EV/EBITDA
WAVE Life Sciences Ltd. (WVE) has a current EV/EBITDA of -5.23. The 5-year average EV/EBITDA is -2.37. The thresholds are as follows: Strongly Undervalued below -8.85, Undervalued between -8.85 and -5.61, Fairly Valued between 0.86 and -5.61, Overvalued between 0.86 and 4.10, and Strongly Overvalued above 4.10. The current Forward EV/EBITDA of -5.23 falls within the Historic Trend Line -Fairly Valued range.
-4.60
EV/EBIT
WAVE Life Sciences Ltd. (WVE) has a current EV/EBIT of -4.60. The 5-year average EV/EBIT is -3.49. The thresholds are as follows: Strongly Undervalued below -9.55, Undervalued between -9.55 and -6.52, Fairly Valued between -0.45 and -6.52, Overvalued between -0.45 and 2.58, and Strongly Overvalued above 2.58. The current Forward EV/EBIT of -4.60 falls within the Historic Trend Line -Fairly Valued range.
25.80
PS
WAVE Life Sciences Ltd. (WVE) has a current PS of 25.80. The 5-year average PS is 13.72. The thresholds are as follows: Strongly Undervalued below -3.98, Undervalued between -3.98 and 4.87, Fairly Valued between 22.57 and 4.87, Overvalued between 22.57 and 31.42, and Strongly Overvalued above 31.42. The current Forward PS of 25.80 falls within the Overvalued range.
-6.68
P/OCF
WAVE Life Sciences Ltd. (WVE) has a current P/OCF of -6.68. The 5-year average P/OCF is -6.15. The thresholds are as follows: Strongly Undervalued below -17.50, Undervalued between -17.50 and -11.82, Fairly Valued between -0.48 and -11.82, Overvalued between -0.48 and 5.19, and Strongly Overvalued above 5.19. The current Forward P/OCF of -6.68 falls within the Historic Trend Line -Fairly Valued range.
-6.82
P/FCF
WAVE Life Sciences Ltd. (WVE) has a current P/FCF of -6.82. The 5-year average P/FCF is -5.42. The thresholds are as follows: Strongly Undervalued below -14.32, Undervalued between -14.32 and -9.87, Fairly Valued between -0.97 and -9.87, Overvalued between -0.97 and 3.48, and Strongly Overvalued above 3.48. The current Forward P/FCF of -6.82 falls within the Historic Trend Line -Fairly Valued range.
WAVE Life Sciences Ltd (WVE) has a current Price-to-Book (P/B) ratio of 9.19. Compared to its 3-year average P/B ratio of -30.28 , the current P/B ratio is approximately -130.35% higher. Relative to its 5-year average P/B ratio of -126.89, the current P/B ratio is about -107.24% higher. WAVE Life Sciences Ltd (WVE) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -12.14%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -25.14% , the current FCF yield is about -100.00% lower.
9.81
P/B
Median3y
-30.28
Median5y
-126.89
-16.60
FCF Yield
Median3y
-12.14
Median5y
-25.14
Competitors Valuation Multiple
The average P/S ratio for WVE's competitors is 2.12, providing a benchmark for relative valuation. WAVE Life Sciences Ltd Corp (WVE) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of -199.11%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of WVE decreased by 38.40% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -4.59 to -10.25.
The secondary factor is the Margin Expansion, contributed 37.65%to the performance.
Overall, the performance of WVE in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is WAVE Life Sciences Ltd (WVE) currently overvalued or undervalued?
What is WAVE Life Sciences Ltd (WVE) fair value?
How does WVE's valuation metrics compare to the industry average?
What is the current P/B ratio for WAVE Life Sciences Ltd (WVE) as of Dec 05 2025?
What is the current FCF Yield for WAVE Life Sciences Ltd (WVE) as of Dec 05 2025?
What is the current Forward P/E ratio for WAVE Life Sciences Ltd (WVE) as of Dec 05 2025?